Summary
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the brand Loxapine; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.
History
Founded in 1998, Elite Pharmaceuticals is a publicly traded, NASDAQ-listed pharmaceutical company specializing in the development and manufacture of oral, controlled-release products. In 2017, Elite expanded its operations with the acquisition of Fenway Pharmaceuticals.
Mission
Elite Pharmaceuticals is committed to delivering safe, effective and affordable products to improve the health of patients worldwide.
Vision
At Elite Pharmaceuticals, our vision is to be a world leader in the development of safe and effective specialty pharmaceuticals that make people's lives better.
Key Team
Ms. Dianne Will (VP of Investor Relations & Corp. Affairs)
Dr. George Kenneth Smith J.D., M.B.A., Ph.D. (VP of Legal)
Dr. Sophy Abraham (Head of Regulatory Affairs)
Mr. Kirko Kirkov (Chief Commercial Officer)
Recognition and Awards
Elite Pharmaceuticals has received a number of awards for its dedication to innovation, excellence, and safety in pharmaceutical development, including the Specialty Pharmaceutical Award for Product Innovation in 2017 and the American Trade Association's Corporate Achievement Award in 2018.
References